When Your Medication Stops Working: ADHD, Menopause, and What Clinicians Are Only Beginning to Understand

A 2026 review from leading European ADHD experts addresses the most underserved intersection in women's ADHD — and finds that evidence-based guidance barely exists yet.

If you're a woman with ADHD in your forties or fifties, there's a good chance you've noticed something unsettling: the medication that used to work is suddenly not working as well. Or you've been slammed with brain fog, emotional volatility, sleep disruption, and difficulty concentrating — and you're not sure whether it's your ADHD getting worse, menopause hitting, or both at once. Or your doctor looked at you blankly when you tried to connect those dots.

A 2026 narrative review published in Drugs & Aging by Dora Wynchank and Sandra Kooij — two of the leading clinical ADHD researchers in Europe — addresses exactly this intersection, and what they find is simultaneously validating and sobering. Validating, because the biology of what you're experiencing is real and well-supported. Sobering, because there are effectively zero randomized controlled trials on ADHD pharmacotherapy in perimenopausal women, and clinical practice is running almost entirely on expert consensus, analogical reasoning, and small observational studies.

The field has not caught up to the patients. This paper is a step toward changing that.

FIRST, SOME ORIENTATION ON TERMS

Perimenopause is the transition period before menopause, typically beginning in a woman's mid-to-late forties, marked by irregular menstrual cycles, fluctuating and progressively declining estrogen and progesterone. This phase can last years and is often when symptoms are most disruptive.

Menopause itself is defined as the moment following 12 consecutive months without a menstrual period. The average age is 51.

Post-menopause is everything after that point, when hormone levels have stabilized at very low levels.

For women with ADHD, the perimenopause phase — with its erratic, fluctuating hormones — tends to be particularly destabilizing, as we'll explore below.

THE BIOLOGY: WHY ESTROGEN MATTERS TO YOUR ADHD MEDICATION

The paper opens with a clear statement of the core mechanism: estrogen is not just a reproductive hormone. In the brain, it acts as a neurosteroid with direct effects on the dopaminergic system.

Specifically, estrogen stimulates dopamine synthesis in the brain, reduces its reuptake and degradation at the synapse, increases serotonin synthesis, and modulates noradrenergic pathways. These are precisely the same pathways that ADHD medications target. In brain regions critically involved in ADHD — the prefrontal cortex and the basal ganglia — these areas are richly supplied with estrogen receptors.

This gives estrogen a natural, endogenous amplifying effect on the neurotransmitter systems that ADHD disrupts. When estrogen levels are high and stable, the dopaminergic system gets a kind of natural boost. When estrogen levels fall — during the late luteal phase of the menstrual cycle, after childbirth, and most dramatically during perimenopause — that boost disappears.

The clinical implication is direct: stimulant medications for ADHD may be more effective when estrogen is high, and less effective when estrogen is low. Women have reported this for decades. The premenstrual week, the postpartum period, perimenopause — these are all low-estrogen windows that women with ADHD consistently describe as periods when their medication suddenly seems to stop working.

Progesterone adds further complexity. Its overall effect on dopaminergic signaling appears antagonistic — particularly through its metabolite allopregnanolone, which can inhibit dopamine release in the prefrontal cortex. This means high progesterone environments may reduce stimulant efficacy and contribute to cognitive slowing and mood lability. Given that the perimenopausal transition involves months to years of erratic, unpredictable fluctuations in both hormones, the pharmacological picture for women with ADHD during this period is genuinely complex.

There's also a pharmacokinetics dimension — the science of how the body processes drugs. Estrogen and progesterone interact with the liver enzymes (specifically CYP2D6 and CYP3A4) that metabolize many medications, including amphetamine and methylphenidate derivatives. Changes in hormone levels during perimenopause may alter how quickly these drugs are processed, affecting plasma concentrations and therefore clinical effects. Changes in body composition during menopause can further affect drug distribution. These effects are theoretically well-grounded but have never been directly studied in perimenopausal women taking ADHD medications — a glaring gap.

THE DIAGNOSTIC MAZE: ADHD OR MENOPAUSE? OFTEN BOTH

One of the most practically urgent sections of this paper addresses diagnosis — or more precisely, the difficulty of accurate diagnosis during perimenopause.

The symptom overlap is substantial. Brain fog, forgetfulness, difficulty concentrating, executive dysfunction, mood swings, irritability, sleep disruption, anxiety, and reduced motivation — all of these appear on the symptom list for both ADHD and perimenopause. For a clinician unfamiliar with either condition, the picture can be profoundly confusing.

The paper draws a clinically useful distinction. In perimenopause, the cognitive difficulties are primarily related to inefficient attention and working memory encoding — often perceived as "memory loss" — while long-term memory storage and recognition typically remain intact. It's the processing and encoding that suffers, not the storage. ADHD, by contrast, involves lifelong deficits in executive control and sustained attention that affect multiple cognitive domains independently of hormonal status. These deficits have been present since childhood.

The key clinical differentiator: ADHD symptoms begin in childhood and persist throughout life. Perimenopausal symptoms emerge in midlife. This history is diagnostic gold. When a woman presents for a first-time ADHD evaluation during perimenopause — which happens more than one might expect, because perimenopause can push previously manageable symptoms above the functional threshold — clinicians must take a detailed childhood symptom history, seek collateral information where possible, and use a structured diagnostic tool like the DIVA-5 to confirm that the symptoms predate menopause.

Crucially, the reverse problem also exists: women who have had ADHD for decades and are now in perimenopause may find that their existing symptoms are dramatically worsening, and their clinician may misattribute everything to menopause and not adjust ADHD pharmacotherapy appropriately.

The paper also notes one practical, empowering tool: mood and cycle-tracking apps such as Clue or Flo. These allow women and their clinicians to visualize how attention, mood, and medication response fluctuate across hormonal phases. This kind of tracking data — inexpensive, accessible, patient-generated — can be powerful for distinguishing hormonal fluctuation effects from underlying ADHD and for guiding clinical decisions about timing and dose adjustments.

THE UNCOMFORTABLE TRUTH: THERE ARE NO CONTROLLED TRIALS

Before discussing what the clinical evidence supports, it is essential to be transparent about how thin that evidence actually is.

There are zero randomized controlled trials of stimulant or non-stimulant ADHD medications specifically in perimenopausal or post-menopausal women.

Not a small number of trials. Zero.

Current clinical practice for this population is based entirely on expert consensus, extrapolation from younger adult cohorts, small observational studies, case reports, and theoretical reasoning from the known biology. The authors, two of the most experienced ADHD clinicians in Europe, are quite direct about this.

This doesn't mean there's no guidance. It means the guidance that exists comes from clinical wisdom rather than controlled evidence, and needs to be understood as such by both patients and prescribers.

STIMULANT MEDICATIONS DURING MENOPAUSE

Methylphenidate, dexamfetamine, and lisdexamfetamine remain the core pharmacological treatments for adult ADHD, and there's no evidence they lose their fundamental mechanism of action during menopause. What the clinical picture suggests is that their effectiveness may fluctuate with hormonal changes, and that dose adjustments may sometimes be needed.

Lisdexamfetamine has perhaps the most relevant evidence base for midlife women — not because of studies in ADHD specifically, but because it has been studied in non-ADHD menopausal women with executive dysfunction. Two studies from Penn (Epperson 2015 and Shanmugan 2017) found that lisdexamfetamine improved executive function in menopausal women experiencing cognitive difficulties — without the women having ADHD diagnoses. This is suggestive evidence that the medication addresses the specific type of cognitive dysfunction that menopause exacerbates, though it doesn't prove anything about the ADHD+menopause intersection directly.

Many women report that their standard doses feel insufficient during perimenopause and that dose increases help. One small study from the paper's own research group (de Jong et al., 2023 — which appeared as the basis for a blog we published earlier) found that increasing psychostimulant doses premenstrually improved both ADHD symptoms and mood. The underlying hormonal mechanism is the same; perimenopause is simply a more sustained version of the hormonal challenge.

The paper also addresses cardiovascular monitoring — which deserves emphasis. ADHD itself confers elevated cardiometabolic risk independent of medication (for hypertension, obesity, and cardiovascular disease). Stimulants add a modest additional increment. Menopause also increases cardiovascular risk as estrogen's protective effects on blood vessels diminish. The convergence of these three factors — ADHD, stimulant use, and menopause — makes regular cardiovascular monitoring (blood pressure, pulse, weight) essential in this population.

HORMONE THERAPY AS AN ADJUNCT: THE EMERGING PICTURE

One of the most clinically significant sections of this paper deals with Menopausal Hormone Therapy (MHT) — previously called hormone replacement therapy — and its potential role as an adjunctive strategy for women with ADHD navigating menopause.

MHT is not a treatment for ADHD. There are no controlled trials establishing it as such. But its documented effects on the very domains that intersect most painfully with ADHD — cognition, sleep, mood, and vasomotor symptoms — make it potentially important as part of the clinical picture.

Here is what the evidence shows for MHT more broadly: initiated early (within 10 years of menopause onset, or in women under 60), MHT reduces all-cause mortality by approximately 30-40%, reduces coronary heart disease risk by roughly 30-50%, reduces osteoporosis and fracture risk by 20-40%, and consistently improves perimenopausal mood and low mood. These are substantial effects with an updated, more favorable benefit-risk profile than what many people remember from older Women's Health Initiative data — a study whose risks have been substantially recontextualized by subsequent analyses.

For cognitive effects specifically, a 2024 meta-analysis found that estrogen therapy initiated close to menopause onset was associated with improved verbal memory. The overall effect on broad cognitive domains is less clear, but the timing matters — what's been called the "timing hypothesis."

For women with ADHD specifically, the potential benefits of MHT are indirect but real. Hot flushes and night sweats that disrupt sleep worsen ADHD-related cognitive and mood symptoms. MHT, by stabilizing hormonal fluctuations, may reduce these symptoms and thereby secondarily improve ADHD-relevant functioning. Mood disturbances linked to estrogen decline — which are particularly prevalent in women with ADHD — may be improved by estrogen therapy. This isn't MHT treating ADHD; it's MHT removing obstacles that are making ADHD worse.

Regarding formulation: the paper's authors are clear about their preferred approach. Transdermal estrogen (patches or gels) is recommended over oral forms because it avoids the increased risk of venous thromboembolism and stroke associated with oral estrogen, doesn't raise triglyceride levels, and carries a more favorable cardiovascular and breast cancer safety profile. For women with a uterus, estrogen is combined with oral micronised progesterone (not synthetic progestogens), which has a better safety profile regarding breast tissue.

Their typical starting regimen: transdermal oestradiol patch 50µg twice weekly plus daily micronised progesterone 100mg at night.

THE CLINICAL SEQUENCE THAT MATTERS

One of the most practically useful pieces of guidance in this paper is about sequencing — what to change, and in what order.

When a perimenopausal woman with ADHD is already on an optimally titrated stimulant with minimal side effects, but continues to experience perimenopausal symptoms, the recommendation is: add MHT where clinically indicated rather than adjusting ADHD medication preemptively.

The reasoning is clear. MHT targets the non-ADHD domains that are magnifying cognitive and emotional difficulties — vasomotor symptoms, sleep disruption, mood. By addressing those, MHT may indirectly improve daytime attention and executive functioning without requiring changes to stimulant therapy. And when one intervention has already been working, changing it preemptively creates confusion about what's causing what.

The principle: one change at a time. This allows clinicians and patients to clearly identify which intervention is producing benefit or causing side effects.

Only if MHT alone is insufficient, or if ADHD symptoms genuinely worsen beyond what MHT resolves, would dose adjustment of ADHD medication be considered.

A FINDING THAT DESERVES MORE ATTENTION: EARLIER MENOPAUSE IN ADHD

Among several important findings in this paper, one stands out as particularly under-discussed: women with ADHD appear to reach natural menopause earlier.

This association has been reported in a genome-wide association study and in a population study from Iceland. The biological explanation remains to be worked out. But the health implications are significant: earlier onset of natural menopause — before age 45 — is linked to higher risks of all-cause mortality, cardiovascular disease, osteoporosis, type 2 diabetes, and Alzheimer's disease.

If women with ADHD are disproportionately experiencing early menopause, they may be entering an extended lower-estrogen period sooner than their peers, with all the associated health risks compounded by the neurobiological vulnerabilities that ADHD already confers. This is a population health finding that demands dedicated follow-up research.

WHAT WOMEN WITH ADHD NEED FROM THEIR CLINICIANS RIGHT NOW

This paper is honest about the limits of available evidence. There are no RCTs. Current guidance is expert-based, not trial-based. The field is years behind where it needs to be.

But there are things clinicians can and should do now, and the paper provides them:

Know that perimenopause can dramatically worsen ADHD symptoms and reduce medication effectiveness. Don't dismiss these reports.

Take a thorough childhood symptom history when women present with cognitive or attention complaints during the menopausal transition. The DIVA-5 structured interview is the appropriate tool.

Encourage cycle and mood tracking to identify hormonal patterns in symptom severity and medication response.

Consider MHT as a clinically appropriate adjunct for eligible women — not to treat ADHD directly, but to stabilize the hormonal conditions that are undermining ADHD management.

Monitor cardiovascular health proactively, given the compound risk profile of ADHD, stimulant use, and menopause.

Work collaboratively with gynecologists, cardiologists, and other specialists — because this intersection demands it.

And most importantly: believe the women who tell you their medication stopped working when their periods changed. The biology supports them entirely.

WHAT THIS PAPER ADDS TO THE FIELD

This review brings something genuinely needed to the ADHD literature: a clinical framework for a population that has been essentially invisible in the research. It draws on the biology of the estrogen-dopamine relationship, the pharmacokinetics of sex hormone effects on drug metabolism, the clinical challenge of differential diagnosis, the evidence base for MHT, and the practical sequencing wisdom of experienced clinicians.

It doesn't have controlled trial data to cite, because that data doesn't exist yet. What it has is a clear map of what's known, what's unknown, and what needs to be researched. And for the women and clinicians navigating this intersection right now — with no map and mounting frustration — this paper provides a better starting point than almost anything that preceded it.

The authors call for controlled trials. They are right. Until those trials exist, this paper is as close to a roadmap as we have.

A NOTE ON THE STUDY

"Pharmacological Management of ADHD in Women Across Perimenopause, Menopause and Post-Menopause" was published in Drugs & Aging in 2026 (Vol. 43, pp. 385-395) by Dora Wynchank and Sandra Kooij, PsyQ Expertise Centre Adult ADHD, The Hague and Amsterdam University Medical Center, The Netherlands. No external funding was received. The authors are founders and owners of the ADHD Powerbank, an online ADHD educational platform; this relationship was disclosed.

---

At ADHD Awearness, we exist to bring this science to the people who need it. If this post reflected your experience, share it with someone who needs to feel seen.